Compare CGO & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGO | KRRO |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.4M | 142.0M |
| IPO Year | 2004 | 2019 |
| Metric | CGO | KRRO |
|---|---|---|
| Price | $12.03 | $8.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | 23.9K | ★ 194.3K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $56.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $10.71 | $5.20 |
| 52 Week High | $14.20 | $55.89 |
| Indicator | CGO | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 29.84 | 35.47 |
| Support Level | $11.27 | $8.29 |
| Resistance Level | $12.11 | $9.59 |
| Average True Range (ATR) | 0.37 | 0.66 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 5.88 | 27.05 |
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.